Source - GNW

TR-1: Standard form for notification of major holdings

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: Summit Therapeutics PLC
Sedol BN40HZ0
1b. Please indicate if the issuer is a non-UK issuer  (please mark with an "X" if appropriate)
Non-UK issuer  
2. Reason for the notification (please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights  
An acquisition or disposal of financial instruments  
An event changing the breakdown of voting rights X
Other (please specify)iii:  
3. Details of person subject to the notification obligationiv
Name 1Lansdowne Partners International Limited

2Lansdowne Partners Limited

3Lansdowne Partners (UK) LLP
City and country of registered office (if applicable) London, United Kingdom
4. Full name of shareholder(s) (if different from 3.)v
Name  

HSBC Client Holdings Nominee (UK) Ltd
HSBC Bank Plc Lansdowne Markets
Morgan Stanley Client Securities Nominees Limited

 

(Registered Shareholders)

 
City and country of registered office (if applicable) N/A
5. Date on which the threshold was crossed or reachedvi: 11/10/2017
6. Date on which issuer notified (DD/MM/YYYY): 12/10/2017
7. Total positions of person(s) subject to the notification obligation
  % of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B) Total number of voting rights of issuervii
Resulting situation on the date on which threshold was crossed or reached 15.68% 11.30% 26.99% 70,629,352
Position of previous notification (if
applicable)
15.75% 11.35% 27.11%  


8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii
A: Voting rights attached to shares
Class/type of
shares

ISIN code (if possible)
Number of voting rightsix% of voting rights
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
GB00BN40HZ01   11,077,170   15.68%
         
         
SUBTOTAL 8. A 11,077,170 15.68%
 

 
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrumentExpiration
date
x
Exercise/
Conversion Period
xi
Number of voting rights that may be acquired if the instrument is
exercised/converted.
% of voting rights
American Depositary Shares (ADS) N/A N/A 7,983,330 11.30%
    SUBTOTAL 8. B 1 7,983,330 11.30%
 

 
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrumentExpiration
date
x
Exercise/
Conversion Period
xi
Physical or cash
settlementxii
Number of voting rights % of voting rights
           
           
     SUBTOTAL 8.B.2    
 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii  
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)
X
Namexv% of voting rights if it equals or is higher than the notifiable threshold% of voting rights through financial instruments if it equals or is higher than the notifiable thresholdTotal of both if it equals or is higher than the notifiable threshold
Lansdowne Partners
International Limited
15.68% 11.30% 26.99%
Lansdowne Partners
Limited
     
Lansdowne Partners (UK) LLP 15.68% 11.30% 26.99%
 
10. In case of proxy voting, please identify:
Name of the proxy holder  
The number and % of voting rights held  
The date until which the voting rights will be held  
 
11. Additional informationxvi
 

Place of completion London
Date of completion 12 October 2017



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Summit Therapeutics plc via Globenewswire